Weiss Ratings Reiterates “Sell (D-)” Rating for Vor Biopharma (NASDAQ:VOR)

Vor Biopharma (NASDAQ:VOR)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. Stifel Nicolaus raised shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Wednesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Zacks Research raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 10th. Finally, Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vor Biopharma has a consensus rating of “Hold” and an average price target of $113.83.

Vor Biopharma Stock Down 5.0%

VOR opened at $31.72 on Wednesday. The stock has a market cap of $217.41 million, a P/E ratio of -0.12 and a beta of 2.07. The business’s fifty day moving average price is $37.95. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Insider Transactions at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 27,624 shares of the business’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $33.84, for a total value of $934,796.16. Following the sale, the insider directly owned 1,498,921 shares in the company, valued at approximately $50,723,486.64. The trade was a 1.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 897,057 shares of company stock valued at $17,773,312. Insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Vor Biopharma in the 2nd quarter valued at about $66,000. Money Concepts Capital Corp raised its stake in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma during the first quarter valued at about $100,000. Finally, Two Sigma Investments LP increased its position in shares of Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after buying an additional 25,930 shares during the period. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.